ZT-002 is under clinical development by Beijing QL Biopharmaceutical and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZT-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZT-002 overview
ZT-002 is under development for the treatment of type-2 diabetes, obesity, alzheimer's disease and metabolic dysfunction-associated steatohepatitis (non-alcohol related steatohepatitis or MASH or NASH). It is administered through subcutaneous route. The therapeutic candidate is a ultra-long-acting GLP-1 receptor agonist. It is being developed based on quality peptide long-acting technology platform (QLLong).
Beijing QL Biopharmaceutical overview
Beijing QL Biopharmaceutical (QL Biopharma) operate in healthcare sector. QL Biopharma is headquartered in Beijing, China.
For a complete picture of ZT-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
